Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Hertzel C Gerstein,Helen M Colhoun,Gilles R Dagenais,Rafael Diaz,Mark Lakshmanan,Prem Pais,Jeffrey Probstfield,Fady T Botros,Matthew C Riddle,Lars Rydén,Denis Xavier,Charles Messan Atisso,Leanne Dyal,Stephanie Hall,Purnima Rao-Melacini,Gloria Wong,Alvaro Avezum,Jan Basile,Namsik Chung, Ignacio Conget,William C Cushman,Edward Franek,Nicolae Hancu,Markolf Hanefeld,Shaun Holt,Petr Jansky,Matyas Keltai,Fernando Lanas,Lawrence A Leiter,Patricio Lopez-Jaramillo,Ernesto German Cardona Munoz,Valdis Pirags,Nana Pogosova,Peter J Raubenheimer,Jonathan E Shaw,Wayne H-H Sheu,Theodora Temelkova-Kurktschiev The Lancet（2019）
Abstract
Eli Lilly and Company.
MoreTranslated text
Key words
Diabetes,Type 2 Diabetes,Type 1 Diabetes,Continuous Glucose Monitoring,Glucose Control
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
